Digital Pathway - The Evolving Landscape of LDL-C Reduction in High Risk Patients: Optimizing Combination Therapy to Reduce ASCVD Risk

Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps. During this activity, experts discuss the efficacy and safety of these new approaches, how they fit in with the current treatment options for LDL-C lowering, as well as their application to patient care.

The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.

This activity is part of CMHC's Lipid Management Digital Education Hub. 

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk. 
  • Interpret the data from across major trials and real-world studies with PCSK9 inhibitors and their implications for patient selection.
  • Review the new approaches with novel LDL-C lowering agents and their potential impact in ASCVD risk reduction.
  • Select individualized treatment strategies for hypercholesterolemic patients that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Course opens: 
11/04/2022
Course expires: 
11/04/2023
Rating: 
0


Christie M. Ballantyne, MD
Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX

Dr. Ballantyne discloses the following:

Consulting Fee (e.g., Advisory Board): Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken*, Esperion, Genetech, Gilead, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron, Roch Diagnostic, Sanofi-Synthelabo
Contracted Research (Principal Investigators must provide information, even if received by the institution): Grant/Research Support - All Significant (All paid to institution, not individual): Abbott-Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Novartis, Novo Nordisk, Regeneron, Roch Diagnostic

 

Erin D. Michos, MD, MHS 
Associate Professor of Medicine (Cardiology) and Epidemiology 
Director of Women’s Cardiovascular Health 
Associate Director of Preventive Cardiology 
Johns Hopkins University School of Medicine 
Baltimore, MD

Dr. Michos discloses the following:

Consulting Fee (e.g., Advisory Board): AstraZeneca, Amarin, Bayer, Boehringer Inghelheim, Esperion, Novartis, Novo Nordisk, Pfizer

 

Robert S. Rosenson, MD
Professor of Cardiology and Director of Metabolism and Lipids 
Icahn School of Medicine at Mount Sinai 
New York, NY

Dr. Rosenson discloses the following:

Consulting Fee (e.g., Advisory Board): Amgen, Lilly, Novartis, Regeneron
Contracted Research (Principal Investigators must provide information, even if received by the institution): Grants to institution: Amgen, Arrowhead, Lilly, Novartis, Regeneron
Honoraria: Amgen, Kowa, Lilly

Nihar R. Desai, MD, MPH 
Associate Professor of Medicine 
Yale School of Medicine, Section of Cardiovascular Medicine 
New Haven, CT

Dr. Desai discloses the following:

Consulting Fee (e.g., Advisory Board): Amgen, Astra Zeneca, Bayer, Bristol Myers Squibb, Cytokinetics, Novartis, SC Pharmaceuticals, Vifor
Contracted Research (Principal Investigators must provide information, even if received by the institution): Amgen, Astra Zeneca, Cytokinetics, Novartis, Vifor

ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hours

EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians

PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-244-H01-P.

This is a knowledge-based activity. 

DIETICIAN ACCREDITATION STATEMENT
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

CDR learners may submit their program evaluation directly to the CDR.

GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com..

DISCLOSURES

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or ManagerReported Financial Relationship
Rhys Williams, MSN, FNP-C, RNNothing to disclose.
Lindsay BorvanskyNothing to disclose.
Andrea FunkNothing to disclose.
Liddy KnightNothing to disclose.
Ashley CannNothing to disclose.
Karin McAdamsNothing to disclose.
Shpetim Karandrea, PhDNothing to disclose.
Neha Agarwal, PhDNothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

This activity is complimentary and available during the period November 4, 2022 through November 4, 2023. Participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. 

For questions about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.